论文部分内容阅读
目的观察重组人血管内皮抑制素(恩度)治疗恶性胸腔积液的近期疗效,评价恩度局部应用的疗效、安全性及耐受性。方法将病例随机分为两组:A组(治疗组)18例,B组(对照组)14例。治疗组胸腔注入恩度30 mg+0.9%氯化钠注射液40 m l;对照组胸腔注入顺铂40 mg+0.9%氯化钠注射液60 m l,每周2次,共2~4次。结果 A组(治疗组)中CR 5例,PR 9例,ND 4例,有效率77.8%。B组(对照组)CR2例,PR5例,ND7例,有效率50%。A组副反应较轻。结论顺铂和恩度胸腔灌注治疗恶性胸腔积液,均能有效控制恶性胸腔积液,但恩度有效率高于顺铂组,而且副反应较轻。
Objective To observe the short-term curative effect of recombinant human endostatin (Endostar) in the treatment of malignant pleural effusion and evaluate the efficacy, safety and tolerability of Endostar. Methods The cases were randomly divided into two groups: A group (treatment group) 18 cases, B group (control group) 14 cases. The control group was injected with Thirty (30 mg) + 0.9% Sodium Chloride Injection (40 mg) in the thoracic cavity of the treatment group, and 60 ml of cisplatin 40 mg + 0.9% sodium chloride injection in the control group. The control group was injected twice a week for 2 to 4 times. Results In group A (treatment group), 5 cases were CR, 9 cases were PR, and 4 cases were ND. The effective rate was 77.8%. Group B (control group) CR2 cases, PR5 cases, ND7 cases, the effective rate of 50%. A group of minor side effects. Conclusions Both cisplatin and Endothymus perfusion in the treatment of malignant pleural effusion can effectively control malignant pleural effusion, but the baud rate is higher than that of cisplatin group, and the side effects are mild.